First-Line Treatment for Yeast Infection

Treatment Algorithm by Clinical Presentation

The Infectious Diseases Society of America recommends using either topical azole antifungals or a single oral dose of fluconazole 150 mg as first-line options for uncomplicated vulvovaginal candidiasis, with A-I level evidence 1, 2, 3, 4
Topical azole agents, such as clotrimazole or miconazole, can be applied intravaginally for 1-7 days, depending on the formulation, as a primary option for uncomplicated vulvovaginal candidiasis 1, 2, 3, 4
Oral fluconazole 150 mg as a single dose is also a primary option for uncomplicated vulvovaginal candidiasis, with 92-99% clinical cure rates at short-term evaluation and 88-91% efficacy at long-term follow-up 1, 2, 3, 4
For recurrent vulvovaginal candidiasis, initial treatment with fluconazole 150 mg single dose, followed by maintenance therapy with fluconazole 150 mg weekly for 6 months, is recommended 1, 2, 3, 4
Addressing predisposing factors, including uncontrolled diabetes, antibiotic use, immunosuppression, and poor hygiene, is crucial in managing recurrent vulvovaginal candidiasis 5

Topical azole antifungals are the first-line treatment for uncomplicated male genital yeast infections 5
For fluconazole-resistant organisms, alternative agents such as amphotericin B deoxycholate or echinocandins can be used 1, 2, 3, 4
Azole therapy should not be used in patients with recent azole exposure or prophylaxis, as it increases the risk of resistance 1, 2, 3, 4
Asymptomatic candiduria in males does not require treatment unless the patient is neutropenic or undergoing urologic procedures 5